首站-论文投稿智能助手
典型文献
Efficacy and safety of acupoint application for allergic rhinitis:a systematic review and Meta-analysis of randomized controlled trials
文献摘要:
OBJECTIVE:To use evidence-based medicine to explore the efficacy of acupoint application(AA)for allergic rhinitis(AR)at different time points and its safety.METHODS:We searched 7 databases(PubMed,Cochrane,Embase,China National Knowledge Infrastructure,Wanfang Database,China Science and Technology Journal Database,and China Biology Medicine disc)as well as the international clinical trial registration platform from January 2010 to March 2020 for randomized controlled trials(RCTs)comparing the efficacy of AA versus placebo,Western Medicine or other alternative therapies on AR.Risk of bias was assessed according to the Cochrane handbook,and statistical analysis was performed using RevMan 5.3.Outcomes included the total effective rate,recurrence rate,total nasal symptom score(TNSS),visual analogue scale(VAS),quality of life measured by the Rhinitis Quality of Life Questionnaire(RQLQ)or Short Form-36(SF-36),adverse events,and biomarkers including immunoglobulin E(IgE),peripheral blood eosinophil count(EOS),interleukin-4(IL-4),and interferon gamma(INF-y).RESULTS:Twenty-eight RCTs involving 3282 participants were included.The short-term and long-term efficacy of AA was significantly better than placebo,including better total effective rate[RR:3.05,95%CI(1.84,5.07),after treatment;RR:9.29,95%CI(2.57,33.66),at 6 months],lower recurrence rate[RR:0.55,95%CI(0.45,0.66),at 6 months;RR:0.65,95%CI(0.57,0.74),at 1 year],lower TNSS[MD:-3.09,95%CI(-3.58,-2.61),after treatment],and lower RQLQ[MD:-14.79,95%CI(-21.49,-8.10),after treatment;MD:-11.92,95%CI(-17.40,-6.45),at 4-6 months].Compared with Western Medicine,AA had better long-term total effective rate[RR:1.33,95%CI(1.05,1.69),at 3 months;RR:1.49,95%CI1.22 to 1.81,at 1 year)and lower recurrence rate[RR:0.48,95%CI(0.39,0.58),at 6 months;RR:0.45,95%CI(0.33,0.60),at 1 year].AA had better long-term total effective rate versus acupuncture[RR:2.06,95%CI(1.28,3.31),at 1 year]or oral Chinese medicine[RR:1.21,95%Cl(1.09,1.34),2 6 months].Both AA and Western Medicine can reduce serum levels of IgE,EOS,and IL-4 after treatment.The main adverse event of AA was local skin reaction without systemic side effects.CONCLUSIONS:The short-term(within one month)and long-term(at 3 months,6 months and 1 year)efficacy of acupoint application on AR was better than that of placebo.The long-term efficacy of acupoint application was superior to that of Western Medicine(at 3 months,6 months and 1 year),oral Chinese medicine(at more than 6 months)and acupuncture(at 1 year).AA can reduce serum IgE,EOS,and IL-4 level of AR patients in a short run.Acupoint application is safe,but severe skin reactions can reduce patient compliance.
文献关键词:
作者姓名:
SHEN Mengxia;SHANG Wenfang;WU Jiangxia;YU Zelin;XUAN Lihua
作者机构:
First School of Clinical Medicine of Zhejiang Chinese Medical University,Hangzhou 310053,China;Department of acupuncture and moxibustion,the First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310006,China
引用格式:
[1]SHEN Mengxia;SHANG Wenfang;WU Jiangxia;YU Zelin;XUAN Lihua-.Efficacy and safety of acupoint application for allergic rhinitis:a systematic review and Meta-analysis of randomized controlled trials)[J].中医杂志(英文版),2022(06):858-868
A类:
B类:
Efficacy,safety,acupoint,application,allergic,rhinitis,systematic,review,analysis,randomized,controlled,trials,OBJECTIVE,To,use,evidence,medicine,explore,efficacy,AA,different,points,its,METHODS,searched,databases,Cochrane,Embase,China,National,Knowledge,Infrastructure,Wanfang,Database,Technology,Journal,Biology,Medicine,disc,well,international,clinical,registration,platform,from,January,March,RCTs,comparing,versus,placebo,other,alternative,therapies,Risk,bias,was,assessed,according,handbook,statistical,performed,using,RevMan,Outcomes,included,total,effective,rate,recurrence,nasal,symptom,score,TNSS,visual,analogue,scale,VAS,quality,life,measured,by,Rhinitis,Quality,Life,Questionnaire,RQLQ,Short,Form,SF,adverse,events,biomarkers,including,immunoglobulin,IgE,peripheral,blood,eosinophil,count,EOS,interleukin,interferon,gamma,INF,RESULTS,Twenty,eight,involving,participants,were,short,term,long,significantly,better,than,RR,after,treatment,months,lower,year,MD,Compared,had,CI1,acupuncture,oral,Chinese,Cl,Both,reduce,serum,levels,main,local,skin,without,systemic,side,effects,CONCLUSIONS,within,one,that,superior,more,patients,run,Acupoint,but,severe,reactions,compliance
AB值:
0.467036
相似文献
Efficacy of Lycium barbarum polysaccharide in adolescents with subthreshold depression: interim analysis of a randomized controlled study
Xiaoyue Li;Xuan Mo;Tao Liu;Robin Shao;Kayla Teopiz;Roger S.McIntyre;Kwok-Fai So;Kangguang Lin-Department of Affective Disorders,The Affiliated Brain Hospital of Guangzhou Medical University(Guangzhou Huiai Hospital),Guangzhou,Guangdong Province,China;Laboratory of Emotion and Cognition,The Affiliated Hospital of Guangzhou Medical University(Guangzhou Huiai Hospital),Guangzhou,Guangdong Province,China;Department of Psychiatry,The Fifth Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong Province,China;Canadian Rapid Treatment Center of Excellence,Mississauga,ON,Canada;Mood Disorders Psychopharmacology Unit,Poul Hansen Family Centre for Depression,University,Health Network,Toronto,ON,Canada;Department of Psychiatry,University of Toronto,Toronto,ON,Canada;Brain and Cognition Discovery Foundation,Toronto,ON,Canada;Ministry of Education Joint International Research Laboratory of CNS Regeneration,Jinan University,Guangzhou,Guangdong Province,China;Neuroscience and Neurorehabilitation Institute,University of Health and Rehabilitation Sciences,Qingdao,Shandong Province,China
Reporting and methodological quality of meta-analyses of acupuncture for patients with migraine:A methodological investigation with evidence map
Ting-ting Lu;Cun-cun Lubc;Mei-xuan Li;Li-xin Ke;Hui Cai;Ke-hu Yang-Institution of Clinical Research and Evidence-Based Medicine,Gansu Provincial Hospital,Lanzhou 730000,Gansu Province,China;Evidence-Based Medicine Center,School of Basic Medical Sciences,Lanzhou University,Lanzhou 730000,Gansu Province,China;Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province,Lanzhou 730000,Gansu Province,China;Hepatobiliary and Pancreatic Center,the First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,Guangdong Province,China;General Surgery Clinical Medical Center,Gansu Provincial Hospital,Lanzhou 730000,Gansu Province,China
Can acupuncture enhance therapeutic effectiveness of antidepressants and reduce adverse drug reactions in patients with depression?A systematic review and meta-analysis
Ming-min Xu;Pei Guo;Qing-yu Ma;Xuan Zhou;Yu-long Wei;Lu Wang;Yue Chen;Yu Guo-School of Traditional Chinese Medicine,Jinan University,Guangzhou 510632,Guangdong Province,China;Acupuncture and Tuina School/Third Teaching Hospital,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;School of Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;Guangzhou Key Laboratory of Formula-Pattern of Traditional Chinese Medicine,Formula-Pattern Research Center,Jinan University,Guangzhou 510632,Guangdong Province,China;School of Acupuncture-Moxibustion and Tuina,Beijing University of Chinese Medicine,Beijing 100029,China
A trial of arbidol hydrochloride in adults with COVID-19
Zhao Jingya;Zhang Jinnong;Jin Yang;Tang Zhouping;Hu Ke;Sun Hui;Shi Mengmeng;Yang Qingyuan;Gu Peiyu;Guo Hongrong;Li Qi;Zhang Haiying;Li Chenghong;Yang Ming;Xiong Nian;Dong Xuan;Xu Juanjuan;Lin Fan;Wang Tao;Yang Chao;Huang Bo;Zhang Jingyi;Chen Shi;He Qiong;Zhou Min;Qu Jieming-Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Department of Emergency, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory and Critical Care Medicine, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Respiratory and Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei 430060, China;Department of Endocrinology, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory Medicine, Wuhan Bauhinia Hospital, Wuhan, Hubei 430062, China;Department of Respiratory Medicine, Guanggu Hospital District, The Third Hospital of Wuhan, Wuhan, Hubei 430074, China;Department of Respiratory and Critical Care Medicine, Puren Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China;Department of Respiratory Medicine, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China;Department of Respiratory Medicine, The Sixth General Hospital of Hubei Province, Wuhan, Hubei 430015, China;Tuberculosis Department of Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan 610066, China;Department of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei 430015, China;Department of Tuberculosis, Jinyintan Hospital, Wuhan, Hubei 430048, China;Department of Cardiology, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China
Dynamic changes of renal cortical blood perfusion before and after percutaneous transluminal renal artery stenting in patients with severe atherosclerotic renal artery stenosis
Ma Na;Li Yan;Wang Siyu;Li Mengpu;Li Yongjun;Ai Hu;Zhu Hui;Wang Yang;Guo Fajin;Ren Junhong-Department of Sonography, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Vascular Surgery, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Cardiology, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Nuclear Medicine, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Medical Research & Biometrics Center, National Center for Cardiovascular Diseases and Fuwai Hospital, CAMS and PUMC, Beijing 100037, China
Anlotinib as third-or further-line therapy for short-term relapsed small-cell lung cancer:subgroup analysis of a randomized phase 2 study(ALTER1202)
Jianhua Shi;Ying Cheng;Qiming Wang;Kai Li;Lin Wu;Baohui Han;Gongyan Chen;Jianxing He;Jie Wang;Haifeng Qin;Xiaoling Li-Department of Medical Oncology,Linyi Cancer Hospital,Linyi 276002,China;Department of Thoracic Medical Oncology,Jilin Cancer Hospital,Changchun 130012,China;Department of Internal Medicine,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450003,China;Department of Pulmonary Oncology,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China;Department of Thoracic Medical Oncology,The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University(Hunan Cancer Hospital),Changsha 410031,China;Department of Respiratory Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Respiratory Medicine,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Thoracic Surgery,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Pulmonary Oncology,The Fifth Medical Centre of Chinese PLA General Hospital,Beijing 100039,China;Department of Medical Oncology,Liaoning Cancer Hospital,Shenyang 110042,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。